United States· US:0002-6885_14a2ffe3-1d7e-4d1b-ac44-1698d5f92da4
Baricitinib
A baricitinib product containing baricitinib, registered in United States by Eli Lilly and Company. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Baricitinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AF02 (baricitinib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Baricitinib · ATC L04AF02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of baricitinib costs, country by country.
Normalised to the WHO defined daily dose (3 mg), the median price runs from $26.41 in France to $138.66 in United States — a ×5.2 gap.
- United States: $138.66 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Baricitinib · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- US United States$138.66 (acquisition cost)
- CH Switzerland$62.27
- FR France$26.41
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- BARICITINIB
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- L04AF02
- ATC class
- Baricitinib
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11000268853030 TABLET, FILM COATED in 1 BOTTLE (0002-6885-30)
- ndc110002-6885-30
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
368 interactions on record for baricitinib.
Graded by severity as the source publishes them — 295 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Baricitinib · interactions on record
368 records
- 295 severe
- 67 moderate
- 6 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Baricitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOLUMIANTEli Lilly Nederland B.V., Utrecht
- FinlandOlumiantEli Lilly Nederland B.V.
- FranceOLUMIANT 4 mg, comprimés pelliculésELI LILLY NEDERLAND (PAY-BAS)
- BelgiumOlumiant 4 mgEli Lilly Nederland
- IcelandOLUMIANTEli Lilly Nederland B.V.
- NetherlandsOlumiant 4 mg, filmomhulde tablettenEli Lilly Nederland B.V.
- NorwayOlumiantEli Lilly Nederland B.V.
- PolandOlumiantEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Iceland · Olumiant
- Liechtenstein · Olumiant
- Norway · Olumiant
- Portugal · Baricitinib Generis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7ab28863-60b6-49c0-bf33-80c34b6cc780 GET /v1/drugs/7ab28863-60b6-49c0-bf33-80c34b6cc780?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "4",
"substance": "BARICITINIB",
"productndc": "0002-6885",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": null,
"marketing_category": "EMERGENCY USE AUTHORIZATION"
}See everything about baricitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.